Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Alternative and Complementary Medicine (1)
- Amino Acids, Peptides, and Proteins (1)
- Biochemical Phenomena, Metabolism, and Nutrition (1)
- Biotechnology (1)
- Chemicals and Drugs (1)
-
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)
- Digestive System Diseases (1)
- Digestive, Oral, and Skin Physiology (1)
- Diseases (1)
- Enzymes and Coenzymes (1)
- Life Sciences (1)
- Medical Biotechnology (1)
- Medical Genetics (1)
- Medical Nutrition (1)
- Medical Pharmacology (1)
- Medical Specialties (1)
- Nutritional and Metabolic Diseases (1)
- Other Pharmacy and Pharmaceutical Sciences (1)
- Pharmaceutical Preparations (1)
- Pharmaceutics and Drug Design (1)
- Pharmacy and Pharmaceutical Sciences (1)
- Preventive Medicine (1)
- Keyword
Articles 1 - 2 of 2
Full-Text Articles in Genetic Phenomena
Association Of Body Mass Index Genetic Risk Markers With Body Composition During Adolescence, Brice A. Smoker
Association Of Body Mass Index Genetic Risk Markers With Body Composition During Adolescence, Brice A. Smoker
Senior Theses
Background. Obesity affects nearly a fifth of all children in the United States and is a common risk factor for numerous chronic diseases. Many risk factors contribute to obesity, including race and genetics. Obesity is partially heritable, and many genetic loci have been identified as being associated with body mass index (BMI) in adults. Some of these loci have also been associated with childhood BMI, with effects strengthening with age. A previous genome-wide association study (GWAS) identified five single nucleotide polymorphisms (SNPs) associated with changes in BMI in children aged 1 – 17 years.
Purpose. The purpose of the current …
The Pharmabiotic For Phenylketonuria: Development Of A Novel Therapeutic, Chloé Elizabeth Lebegue
The Pharmabiotic For Phenylketonuria: Development Of A Novel Therapeutic, Chloé Elizabeth Lebegue
Senior Theses
Phenylketonuria, now known as phenylalanine hydroxylase (PAH) deficiency, is a genetic disorder of metabolism affecting approximately one in every 15,000 infants born in the United States. Patients have nonfunctional PAH enzyme secondary to one or more genetic mutations. The enzyme deficit results in destructive supraphysiologic blood phenylalanine levels upon consumption of the essential dietary amino acid phenylalanine. Current standards of care mitigate signs and symptoms of the disorder, but do not approach a cure. The methods for creating a prototype pharmabiotic as an innovative treatment strategy for PAH deficiency are described herein.
DNA molecular cloning techniques were utilized to engineer …